Please assess the completion status of the following clinical trial:

Trial Title: Study of Sequential Topoisomerase, Irinotecan/Oxaliplatin - Etoposide /Carboplatin in Extensive Small Cell Lung Cancer (SCLC)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Histologic or cytologic diagnosis of SCLC.~2. Measurable or assessable tumor parameters.~3. Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2.~4. Age between 18 and 79 years (in the State of Alabama \> 18).~5. Adequate bone marrow, liver and renal function, defined as:~   * Absolute neutrophil count (ANC) ≥ 1500/µL~  * Platelet count ≥ 100,000/µL~  * SGOT/SGPT ≤ 2.5 x upper limit of normal or ≤ 5 x upper limit of normal when liver metastases are present.~  * Total bilirubin value ≤ 1.5 x upper limit of normal.~  * Serum creatinine value ≤ 1.5 x upper limit of normal.~6. Fully recovered from any previous surgery (at least 4 weeks since major surgery)~7. Must have recovered from prior radiation therapy (at least 3 weeks)~8. All participants must agree to practice approved methods of birth control (if applicable). A negative pregnancy test must be documented during the screening period for women of childbearing potential.~9. Must provide written informed consent and authorization to use and disclose health information (HIPAA).~   For Part I~10. Extensive-stage SCLC as defined as disease not confined to one hemithorax, including ipsilateral pleural effusion or pericardial effusion.~11. No prior chemotherapy.~    For Part II~12. Patients with either refractory disease, or who have relapsed 1st line therapy. No prior chemotherapy with Oxaliplatin or irinotecan.~13. Demonstrated tumor progression at the time of study entry.~Exclusion Criteria:~1. Concurrent cancer chemotherapy, biologic therapy or radiotherapy.~2. Administration of any investigational drug within 28 days prior to administration of the current therapy.~3. Symptomatic brain metastases; those patients should be treated first with either whole brain radiation therapy or radiosurgery.~4. Concurrent serious infection.~5. Concomitant severe or uncontrolled underlying medical disease unrelated to the tumor, which is likely to compromise patient safety and affect the outcome of the study.~6. History of other malignancy (except non-melanoma skin cancer or carcinoma in situ of the cervix), unless in complete remission and off all therapy for a minimum of 2 years.~7. Neuropathy at baseline ≥ Grade 2.~8. Any evidence or history of hypersensitivity or other contraindications for the drugs used in this trial.~9. History of chronic diarrhea; or diarrhea (excess of 2-3 stools/day above normal frequency) in the past 2 weeks.~10. History of a positive serology for human immunodeficiency virus (HIV).~11. Psychiatric disorder that prevents patients from providing informed consent or following protocol instructions.~12. Pregnant or lactating women.

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Irinotecan; Oxaliplatin; Neulasta (Type: EXPERIMENTAL): Irinotecan (I.V.) 150-200 mg/m2; Day 1 (every 5 weeks) Oxaliplatin (I.V.) 85 mg/m2; Day 1 (every 5 weeks) Neulasta (subcutaneous) 6 mg; Day 1 (every 5 weeks)
- Etoposide; Carboplatin; Neulasta (Type: EXPERIMENTAL): Etoposide (I.V.) 100 mg/m2; Day 1, 2, 3 (every 5 weeks) Carboplatin (I.V.) area under the concentration curve (AUC) 6; Day 1 (every 5 weeks) Neulasta (subcutaneous) 6 mg; Day 4 (every 5 weeks)

Based on this trial design, predict the completion outcome and termination type (if applicable).